Pharmacoeconomics of trilaciclib in the prevention of chemotherapy-induced myelosuppression
LEI Wei-cheng
GUO Chen-chen
DU Bao-ping
LIU Tao
LIANG Wei-ting
Abstract：Chemotherapy still plays pivotal roles in the comprehensive treatment of tumors.Chemotherapy-induced myelosuppression(CIM)is the most common adverse event of chemotherapy,which has posed serious impacts on the anti-tumor efficacy of chemotherapy and the quality of patients'lives,and also resulted in increased treatment burden of patients and more medical resources at the same time.Trilaciclib is a highly potent,selective,reversible cyclin-dependent kinase 4/6(CDK4/6)inhibitor.Clinical data showed that trilaciclib could temporarily arrest bone marrow cells in G1 phase to reduce the incidences of CIM and the proportion of chemotherapy dose adjustment and delay,increasing the tolerance of chemotherapy and reducing the economic burden.This article systematically elaborates on the CIM-caused hazards,clinical prevention,and current status of treatment of CIM,as well as the roles of trilaciclib in the prevention of CIM and its economic value,aiming to provide scientific reference for patients to select reasonable prevention and therapeutic treatment regimens of CIM.
Keywords：chemotherapymyelosuppressiontrilaciclibpharmacoeconomics
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2354-2359 )